U.S. markets open in 1 hour 8 minutes

CymaBay Therapeutics, Inc. (CBAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.8600-0.2500 (-4.89%)
At close: 4:00PM EST

4.8900 +0.03 (0.62%)
Pre-Market: 8:16AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.1100
Open5.1400
Bid4.8600 x 3200
Ask4.9100 x 2900
Day's Range4.8500 - 5.1800
52 Week Range1.2100 - 9.0600
Volume1,135,688
Avg. Volume1,238,986
Market Cap334.791M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.9390
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.09
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CymaBay Therapeutics to Present at Upcoming Investor Conferences
    GlobeNewswire

    CymaBay Therapeutics to Present at Upcoming Investor Conferences

    NEWARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including the Raymond James 42nd Annual Institutional Investors Conference taking place March 1-3, 2021, the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021, and Oppenheimer’s 31st Annual Healthcare Conference taking place March 16-17, 2021. Raymond James 42nd Annual Institutional Investors ConferenceDate:Time:Webcast:Monday, March 1, 20212:10 pm Eastern Time / Track 4http://ir.cymabay.com/events H.C. Wainwright Global Life Sciences ConferenceDate:Time:Webcast:Tuesday, March 9 , 2021On-Demand 7:00 am Eastern Timehttp://ir.cymabay.com/events Oppenheimer’s 31st Annual Healthcare Conference Date:Time:Webcast:Tuesday, March 16, 20213:50 pm Eastern Timehttp://ir.cymabay.com/events About CymaBay CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. Cautionary Statements Any statements made in this press release and at the investor conferences referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, its current and future clinical trials and CymaBay’s ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law. For additional information about CymaBay visit www.cymabay.com. Public Relations Contact: Glenn SilverLazar-FINN Partners(973) 818-8198Glenn.silver@finnpartners.com Investor Relations Contact: Hans VitzthumLifeSci Advisors, LLC(617) 430-7578Hans@LifeSciAdvisors.com

  • CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
    GlobeNewswire

    CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

    NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leerink 10th Annual Global Healthcare Conference taking place February 22-26, 2021. SVB Leerink 10th Annual Global Healthcare ConferenceDate:Thursday, February 25Time:12 pm Eastern Time/ Track VWebcast:http://ir.cymabay.com/events About CymaBay CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. Cautionary Statements Any statements made in this press release and at the investor conferences referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, its current and future clinical trials and CymaBay’s ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law. For additional information about CymaBay visit www.cymabay.com. Public Relations Contact: Glenn SilverLazar-FINN Partners(973) 818-8198Glenn.silver@finnpartners.com Investor Relations Contact: Hans VitzthumLifeSci Advisors, LLC(617) 430-7578Hans@LifeSciAdvisors.com

  • 5 Disruptive Biotech Stocks With Solid Long-Term Potential
    Zacks

    5 Disruptive Biotech Stocks With Solid Long-Term Potential

    Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.